|1.||Horan, P: 2 articles (01/2005 - 06/2000)|
|2.||Levin, R M: 2 articles (01/2005 - 06/2000)|
|3.||Bellamy, F: 2 articles (01/2005 - 11/2000)|
|4.||Larré, Stéphane: 1 article (05/2012)|
|5.||Boulbés, Delphine: 1 article (05/2012)|
|6.||Comperat, Eva: 1 article (05/2012)|
|7.||Cussenot, Olivier: 1 article (05/2012)|
|8.||Haddoum, Mohammed: 1 article (05/2012)|
|9.||Baulande, Sylvain: 1 article (05/2012)|
|10.||Soularue, Pascal: 1 article (05/2012)|
09/01/1991 - "This clinical study has been designed to evaluate the efficacy of an extract of Pygeum Africanum (Tadenan) (Roussel-Pharma) in patients suffering from prostatic hypertrophy or chronic prostatitis. "
07/01/2008 - "Efficacy of tadenan was studied in combined treatment of 30 patients suffering from chronic prostatitis complicated by sterility. "
07/01/2008 - "[Efficacy of tadenan in chronic prostatitis complicated by sterility]."
|2.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
05/01/2012 - "Pygeum africanum (Tadenan) is a popular phytotherapeutic agent used in the treatment of symptomatic benign prostatic hyperplasia. "
03/01/2009 - "Tadenan, a drug of plant origin, was given to 27 patients with documented prostatic adenoma for 3-12 months. "
03/01/2009 - "[Tadenan treatment of prostatic adenoma]."
09/01/2004 - "[Tadenan (Pygeum africanum extract) in the treatment of patients with benign prostatic hyperplasia]."
05/01/2002 - "Tadenan, an extract of Pygeum africanum, is a therapeutic prescribed in Europe to relieve symptoms of obstructive bladder dysfunction secondary to benign prostatic hyperplasia. "
05/01/2002 - "However, treating obstructed rabbits with 30 mg./kg. Tadenan daily resulted in reduced bladder hypertrophy, improved compliance, improved contractile responses to nearly normal levels of isolated bladder strips to all stimuli tested and reversal of obstruction induced structural damage to cellular and subcellular organelle membranes. "
06/01/2000 - "The alteration in the expression of myosin isoforms associated with obstruction-induced hypertrophy is reversed close to normal in the detrusor smooth muscle from Tadenan-treated obstructed rabbits."
01/01/2005 - "The results of the current study show that Tadenan pretreatment at the clinically relevant dose of 3.0 mg/kg body wt./day protected the bladder from the contractile dysfunctions induced by bilateral ischemia followed by reperfusion. "
01/01/2005 - "The current study was designed to determine whether pre-treating rabbits with a clinically relevant dose of Tadenan could prevent the bladder from developing the contractile dysfunctions that are induced by bilateral ischemia followed by reperfusion. "
01/01/2005 - "These data are consistent with the assertion that Tadenan therapy in both rabbits and humans acts by protecting the bladder smooth muscle against cellular damage caused by ischemia and reperfusion."
01/01/2005 - "Low-dose tadenan protects the rabbit bladder from bilateral ischemia/ reperfusion-induced contractile dysfunction."
|2.||Transforming Growth Factor beta1 (TGF beta 1)
|3.||Protein Isoforms (Isoforms)
|4.||Transforming Growth Factor beta (TGF-beta)
|7.||Fibroblast Growth Factors (Fibroblast Growth Factor)
|1.||Phytotherapy (Herbal Therapy)